Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALDX 
Aldeyra The (ALDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ALDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.67
1 Year Target Price $9.67
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.33% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 293.59M USD | Price to earnings Ratio - | 1Y Target Price 9.67 |
Price to earnings Ratio - | 1Y Target Price 9.67 | ||
Volume (30-day avg) 7 | Beta 0.83 | 52 Weeks Range 1.14 - 7.20 | Updated Date 12/5/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.245 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.94% | Return on Equity (TTM) -64.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 233239114 | Price to Sales(TTM) - |
Enterprise Value 233239114 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.5 | Shares Outstanding 60162773 | Shares Floating 47577924 |
Shares Outstanding 60162773 | Shares Floating 47577924 | ||
Percent Insiders 3.09 | Percent Institutions 66.24 |
Upturn AI SWOT
Aldeyra The
Company Overview
History and Background
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for immune-mediated diseases. Founded in 2004, it has evolved from an early-stage research company to a clinical-stage biopharmaceutical company.
Core Business Areas
- Ophthalmology: Focuses on developing therapies for ocular inflammation and related conditions. Lead product candidate is reproxalap for allergic conjunctivitis and dry eye disease.
- Systemic Immunometabolic Diseases: Developing therapies for systemic immune-mediated diseases by targeting RASP (reactive aldehyde species) activity. Examples include ADX-629.
Leadership and Structure
Todd C. Brady, MD, PhD, is the President and CEO. The company has a board of directors and a management team overseeing research, development, and commercialization activities.
Top Products and Market Share
Key Offerings
- Reproxalap: A reactive aldehyde species (RASP) inhibitor in late-stage development for allergic conjunctivitis and dry eye disease. Market share is not yet established as the product is not yet commercialized. Competitors in the dry eye market include: AbbVie (AGN) (Restasis), Novartis (NVS) (Xiidra), Sun Pharma (Cequa), and Harrow (IHEE) (multiple products). Number of users is currently 0. Revenue is currently 0.
- ADX-629: An orally administered RASP modulator for systemic immune-mediated diseases in early development. Market share is not yet established as the product is not yet commercialized. No direct competitors at this stage as this is a novel therapeutic approach. Number of users is currently 0. Revenue is currently 0.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, with a focus on developing innovative therapies for unmet medical needs. The ocular and systemic inflammatory disease markets are substantial, with significant growth potential.
Positioning
Aldeyra The is positioned as a company focused on novel RASP-modulating therapies for immune-mediated diseases. Its competitive advantage lies in its unique RASP inhibitor technology.
Total Addressable Market (TAM)
The dry eye market TAM is projected to be in the billions of dollars. Aldeyra The aims to capture a significant share of this market with reproxalap. The market for systemic immune-mediated diseases is also substantial, providing significant potential for ADX-629.
Upturn SWOT Analysis
Strengths
- Novel RASP inhibitor technology
- Late-stage clinical programs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
- Need to secure regulatory approvals
- High cash burn rate
Opportunities
- Expanding pipeline through RASP inhibitor technology
- Potential partnerships with larger pharmaceutical companies
- Growing demand for novel therapies for inflammatory diseases
- Regulatory pathways that accelerate approval of new drugs for unmet needs
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- AGN
- NVS
- SUN
- IHEE
Competitive Landscape
Aldeyra faces competition from established pharmaceutical companies with larger resources. Its advantage lies in its novel RASP inhibitor mechanism and targeted approach to inflammatory diseases. Need to gain market share to compete with major players.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been based on advancement of clinical programs. The trajectory is contingent on successful trial outcomes and regulatory approvals.
Future Projections: Future projections are based on analyst estimates and depend on the success of reproxalap and ADX-629. These projections vary based on likelihood of approval and eventual market adoption.
Recent Initiatives: Focus on advancing reproxalap toward potential FDA approval and continuing clinical development of ADX-629.
Summary
Aldeyra The is a clinical-stage biopharmaceutical company focused on novel therapies for immune-mediated diseases. Their lead product, Reproxalap, targets the large dry eye market and it is late stage. They have a novel RASP inhibition platform, but faces the challenges of clinical trials and regulatory hurdles, in addition to competition with large players in the eye and immunology space. The company must succeed in clinical trials to deliver shareholder returns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third Party Industry Data
Disclaimers:
This analysis is based on available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aldeyra The
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. Todd C. Brady M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aldeyra.com |
Full time employees 8 | Website https://www.aldeyra.com | ||
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.